TBF1.F - Canntab Therapeutics Limited

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.3140
-0.0140 (-4.27%)
As of 8:00AM CET. Market open.
Stock chart is not supported by your current browser
Previous Close0.3280
Open0.3140
Bid0.3140 x 0
Ask0.0000 x 0
Day's Range0.3140 - 0.3140
52 Week Range0.2620 - 0.5710
Volume100
Avg. Volume241
Market Cap8.267M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0870
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Canntab Announces Non-Brokered Private Placement
    CNW Group

    Canntab Announces Non-Brokered Private Placement

    TORONTO, Feb. 6, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it is launching a private placement (the "Private Placement") of up to $2.5 million of units ("Units"), subject to the Company's over-allotment option to increase the size of  the Private Placement by up to an additional $1.5 million, at a price of $0.50 per Unit, with each Unit consisting of one common share and one full warrant to acquire an additional common share at a price of $0.75 per share for a period of two years. Canntab expects to close the Private Placement on or before February 20th, 2020. Canntab's expansion through its wholly owned US subsidiary Canntab USA, Inc. into the State of Florida jointly with Exactus Inc. for the manufacture of a CBD hard pill (non-THC) in formulations for sale and distribution across the United States.

  • Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status
    CNW Group

    Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status

    The final step to obtain a licence to process Canntab's cannabis hard pill formulation, at its fully built out Markham, Ontario facility. Retains Larry Latowsky, former CEO of Katz Group Canada and its flagship holding Rexall, as an advisor in order to strengthen Canntab's commercialization efforts. TORONTO, Dec. 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces today the submission of the Company's Site Evidence Package to Health Canada for approval of their Licence Producer Status (Processing-Standard, Federal Sales-Medical).

  • GlobeNewswire

    Exactus, Inc. Enters into Supply & Distribution Agreement with Canntab Therapeutics to Produce Immediate and Extended Release Tablets

    Exactus, Inc. (EXDI) (the “Company”), an industrial hemp farm operator and manufacturer of hemp-derived phytocannabinoid products, today announced that it has entered into a supply and distribution agreement with Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) to produce immediate and extended release tablets. Exactus will provide Canntab a subleased space in their facility in Florida to equip for the purpose of manufacturing advanced hemp derived cannabinoid tablets.

  • CNW Group

    Canntab provides corporate update

    Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg, leading to a Health Canada request for authorization to begin full scale production and sale. Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status. A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada.

  • ACCESSWIRE

    Canntab Therapeutics Featured in the Canadian Cannabis Investor Magazine

    TORONTO, ON / ACCESSWIRE / June 24, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA:TBF1.F) (the " Company " or " Canntab "), the leading innovator in hard pill ...

  • ACCESSWIRE

    Canntab Therapeutics to Present at the 9th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5th at 11:20AM PST / 2:20PM EST. Richard Goldstein, co-founder and Chief Executive Officer of Canntab Therapeutics will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges" stated Chris Lahiji, while waiting in the longest TSA line in history.

  • Business Wire

    Canntab Signs Term Sheet with Heritage for Processing Hemp for Sale of CBD Filled Gelcaps

    Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.

  • CNW Group

    Canntab signs term sheet with Heritage for processing hemp for sale of CBD filled gelcaps

    TORONTO, May 30, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQX:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.

  • CNW Group

    Canntab Receives Cultivation Licence for Industrial Hemp

    Additionally, Canntab's application is currently "In Progress" to obtain a Cannabis Licence (Processing- Standard, Federal Sales - Medical) from Health Canada at its Markham, Ontario facility. TORONTO, May 21, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQX:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has received a cultivation licence for industrial hemp from Health Canada pursuant to the Cannabis Act (Canada) (the "Hemp Licence"). Canntab intends to utilize the Hemp License to secure a substantial amount of hemp biomass that it will grow and cultivate for the extraction of cannabidiol ("CBD") and to conduct research on high CBD hemp varieties, complementing the Company's business plan to also manufacture CBD gel capsules for distribution through its partners in Canada, Australia and Mexico.

  • CNW Group

    Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada

    TORONTO, April 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab") is pleased to announce that by virtue of FSD Pharma Inc. ("FSD"), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a "sale for medical purposes" licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the "FSD Licence"), Canntab is close to being in a position to sell its products and generate revenue. The FSD Licence allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD's Health Canada approved facility in Cobourg, Ontario.

  • GlobeNewswire

    Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services

    Canntab Therapeutics Limited (CSE:PILL) (the “Company” or “Canntab”) is pleased to announce that, effective March 21, 2019, it has engaged Relations Publiques Paradox Inc. (“Paradox”) to provide investor relations services to the Company. Paradox is a Montreal based investor relations consultancy firm that has been in business for 20 years, and is led by entrepreneur, Jean-Francois Meilleur. Paradox has represented a number of public companies through its extensive network and experience in the capital markets.

  • GlobeNewswire

    Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

    Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD $5.0 million of the Supplier’s hemp crop for a period of 5 years commencing in 2019 at a purchase price of CAD $100.0 per kg per 1% of CBD extracted from the flower.

  • GlobeNewswire

    Canntab Provides Corporate Update

    Moving into FSD Pharma and FSD Processing LicenseMackie Research ExtensionDirector Estate Planning InitiativeOTCQB under symbol CTABF TORONTO, Feb. 19, 2019 -- Canntab.